Form 4: Eton Pharmaceuticals CEO Receives Stock Grant
Insider Transaction (Form 4)
Sean Brynjelsen, President & CEO and a Director of Eton Pharmaceuticals, Inc., received 128,985 shares of common stock on July 31, 2026.
Summary
- Grant/award: acquired 128,985 Common Stock on July 31, 2026; holds 128,985 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Sean Brynjelsen — Director, Officer (President & CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-31 | Grant/award | Common Stock | 128,985 | — | — | 128,985 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-31 | Grant/award (128,985 shares) |
Keywords
insider transaction, Form 4, ETON, Eton Pharmaceuticals, Inc., neutral, Sean Brynjelsen
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.